Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 35

References for PMC Articles for PubMed (Select 20216301)

1.

Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study.

Tedaldi E, Peters L, Neuhaus J, Puoti M, Rockstroh J, Klein MB, Dore GJ, Mocroft A, Soriano V, Clotet B, Lundgren JD; SMART Study Group and International Network for Strategic Initiatives in Global HIV Trials (INSIGHT).

Clin Infect Dis. 2008 Dec 1;47(11):1468-75. doi: 10.1086/593102.

2.

Expression of CXC chemokine IP-10 in patients with chronic hepatitis B.

Wang J, Zhao JH, Wang PP, Xiang GJ.

Hepatobiliary Pancreat Dis Int. 2008 Feb;7(1):45-50.

3.

Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.

Nüesch R, Ananworanich J, Srasuebkul P, Chetchotisakd P, Prasithsirikul W, Klinbuayam W, Mahanontharit A, Jupimai T, Ruxrungtham K, Hirschel B.

AIDS. 2008 Jan 2;22(1):152-4.

PMID:
18090405
4.

The HBV drug entecavir - effects on HIV-1 replication and resistance.

McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M, Xing S, Bhat S, Hale B, Hegarty R, Chong CR, Liu JO, Siliciano RF, Thio CL.

N Engl J Med. 2007 Jun 21;356(25):2614-21.

5.
6.

CD4+ count-guided interruption of antiretroviral treatment.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C.

N Engl J Med. 2006 Nov 30;355(22):2283-96.

7.

Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.

Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, Cooper DA, Lewin S, Dore GJ, Thio CL.

AIDS. 2006 Apr 4;20(6):863-70.

PMID:
16549970
8.

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.

Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, Rozenbaum W, Le Teuff G, Trylesinski A, Piketty C; TECOVIR Study Group.

Hepatology. 2006 Mar;43(3):548-55.

PMID:
16496322
9.

Growing importance of liver disease in HIV-infected persons.

Thomas DL.

Hepatology. 2006 Feb;43(2 Suppl 1):S221-9. Review.

PMID:
16447263
10.

Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.

Benhamou Y, Thibault V, Vig P, Calvez V, Marcelin AG, Fievet MH, Currie G, Chang CG, Biao L, Xiong S, Brosgart C, Poynard T.

J Hepatol. 2006 Jan;44(1):62-7. Epub 2005 Sep 23.

PMID:
16274835
11.

Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir.

Sheldon JA, Corral A, Rodés B, Mauss S, Rockstroh J, Berger F, Schwarze-Zander C, Soriano V.

AIDS. 2005 Nov 18;19(17):2036-8.

PMID:
16260913
12.

Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.

Sheldon J, Camino N, Rodés B, Bartholomeusz A, Kuiper M, Tacke F, Núñez M, Mauss S, Lutz T, Klausen G, Locarnini S, Soriano V.

Antivir Ther. 2005;10(6):727-34.

PMID:
16218172
13.

Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.

Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD; EuroSIDA Group.

AIDS. 2005 Mar 24;19(6):593-601.

PMID:
15802978
14.

Survival in patients with HIV infection and viral hepatitis B or C: a cohort study.

Bonacini M, Louie S, Bzowej N, Wohl AR.

AIDS. 2004 Oct 21;18(15):2039-45.

PMID:
15577625
15.

Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort.

Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA, Dore GJ.

AIDS. 2004 May 21;18(8):1169-77.

PMID:
15166532
16.

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.

Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, Lu B, Cheng AK; 903 Study Team; 907 Study Team.

J Infect Dis. 2004 Apr 1;189(7):1185-92. Epub 2004 Mar 12.

17.

HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy.

Lincoln D, Petoumenos K, Dore GJ; Australian HIV Observational Database.

HIV Med. 2003 Jul;4(3):241-9.

PMID:
12859323
18.

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Muñoz A, Thomas DL; Multicenter AIDS Cohort Study.

Lancet. 2002 Dec 14;360(9349):1921-6.

PMID:
12493258
19.

Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.

Núñez M, Pérez-Olmeda M, Díaz B, Ríos P, González-Lahoz J, Soriano V.

AIDS. 2002 Nov 22;16(17):2352-4.

PMID:
12441815
20.

Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects.

De Luca A, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, Poggio A, Pagano G, Tositti G, Cadeo G, Macor A, Toti M, D'Arminio Monforte A; Italian Cohort Naive Antiretrovirals Study Group.

Arch Intern Med. 2002 Oct 14;162(18):2125-32.

PMID:
12374521
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk